6yno Citations

Atomistic and Thermodynamic Analysis of N6-Methyladenosine (m6A) Recognition by the Reader Domain of YTHDC1.

J Chem Theory Comput 17 1240-1249 (2021)
Related entries: 6ynn, 6zcm, 6zcn, 6zd3, 6zd4, 6zd5, 6zd7, 6zd8, 6zd9, 6zda

Cited: 10 times
EuropePMC logo PMID: 33472367

Abstract

N6-Methyladenosine (m6A) is the most frequent modification in eukaryotic messenger RNA (mRNA) and its cellular processing and functions are regulated by the reader proteins YTHDCs and YTHDFs. However, the mechanism of m6A recognition by the reader proteins is still elusive. Here, we investigate this recognition process by combining atomistic simulations, site-directed mutagenesis, and biophysical experiments using YTHDC1 as a model. We find that the N6 methyl group of m6A contributes to the binding through its specific interactions with an aromatic cage (formed by Trp377 and Trp428) and also by favoring the association-prone conformation of m6A-containing RNA in solution. The m6A binding site dynamically equilibrates between multiple metastable conformations with four residues being involved in the regulation of m6A binding (Trp428, Met438, Ser378, and Thr379). Trp428 switches between two conformational states to build and dismantle the aromatic cage. Interestingly, mutating Met438 and Ser378 to alanine does not alter m6A binding to the protein but significantly redistributes the binding enthalpy and entropy terms, i.e., enthalpy-entropy compensation. Such compensation is reasoned by different entropy-enthalpy transduction associated with both conformational changes of the wild-type and mutant proteins and the redistribution of water molecules. In contrast, the point mutant Thr379Val significantly changes the thermal stability and binding capability of YTHDC1 to its natural ligand. Additionally, thermodynamic analysis and free energy calculations shed light on the role of a structural water molecule that synergistically binds to YTHDC1 with m6A and acts as the hub of a hydrogen-bond network. Taken together, the experimental data and simulation results may accelerate the discovery of chemical probes, m6A-editing tools, and drug candidates against reader proteins.

Reviews citing this publication (3)

  1. RNA N6-Methyladenosine Modifications and Its Roles in Alzheimer's Disease. Zhang R, Zhang Y, Guo F, Li S, Cui H. Front Cell Neurosci 16 820378 (2022)
  2. Characterization of epitranscriptome reader proteins experimentally and in silico: Current knowledge and future perspectives beyond the YTH domain. Miller LG, Demny M, Tamamis P, Contreras LM. Comput Struct Biotechnol J 21 3541-3556 (2023)
  3. Methylation across the central dogma in health and diseases: new therapeutic strategies. Liu R, Zhao E, Yu H, Yuan C, Abbas MN, Cui H. Signal Transduct Target Ther 8 310 (2023)

Articles citing this publication (7)

  1. Structural effects of m6A modification of the Xist A-repeat AUCG tetraloop and its recognition by YTHDC1. Jones AN, Tikhaia E, Mourão A, Sattler M. Nucleic Acids Res 50 2350-2362 (2022)
  2. Mutant NPM1-Regulated FTO-Mediated m6A Demethylation Promotes Leukemic Cell Survival via PDGFRB/ERK Signaling Axis. Xiao Q, Lei L, Ren J, Peng M, Jing Y, Jiang X, Huang J, Tao Y, Lin C, Yang J, Sun M, Tang L, Wei X, Yang Z, Zhang L. Front Oncol 12 817584 (2022)
  3. Fragment Ligands of the m6A-RNA Reader YTHDF2. Nai F, Nachawati R, Zálešák F, Wang X, Li Y, Caflisch A. ACS Med Chem Lett 13 1500-1509 (2022)
  4. Interaction preferences between protein side chains and key epigenetic modifications 5-methylcytosine, 5-hydroxymethycytosine and N6-methyladenine. Hajnic M, Alonso-Gil S, Polyansky AA, de Ruiter A, Zagrovic B. Sci Rep 12 19583 (2022)
  5. Molecular Simulations Matching Denaturation Experiments for N6-Methyladenosine. Piomponi V, Fröhlking T, Bernetti M, Bussi G. ACS Cent Sci 8 1218-1228 (2022)
  6. Recent Advances of RNA m6A Modifications in Cancer Immunoediting and Immunotherapy. Ma S, Barr T, Yu J. Cancer Treat Res 190 49-94 (2023)
  7. Structure-Based Design of Inhibitors of the m6A-RNA Writer Enzyme METTL3. Bedi RK, Huang D, Li Y, Caflisch A. ACS Bio Med Chem Au 3 359-370 (2023)